- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 103,520 | 24.09.24 17:35:52 | -0,220 | -0,21% | 0,000 | 0,000 | 103,580 | 103,740 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.045,980 | 24.09.24 22:00:11 | -46,000 | -4,21% | 1.024,400 | 1.050,000 | 1.076,330 | 1.091,980 |
